Jerry Stallings
Family · Woodworth, LANPI 1669623609
Payments from drug & device makers
Across 425 payments — averaging $16.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Novo Nordisk$820
- AstraZeneca$583
- GSK$448
- Axsome Therapeutics, Inc.$356
- Lilly USA, LLC$295
- plus $2K from 29 others
What the payments were for
- Food & beverage$7,115100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 127 | $2,178 |
| Novo Nordisk | 59 | $820 |
| AstraZeneca | 28 | $583 |
| GSK | 25 | $448 |
| Axsome Therapeutics, Inc. | 19 | $356 |
| Lilly USA, LLC | 17 | $295 |
| Merck | 14 | $240 |
| Otsuka America Pharmaceutical, Inc. | 12 | $237 |
| Takeda Pharmaceuticals U.S.A., Inc. | 12 | $218 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 10 | $191 |
| Pfizer | 11 | $184 |
| Dexcom, Inc. | 12 | $163 |
| Teva Pharmaceuticals USA, Inc. | 6 | $126 |
| Sunovion Pharmaceuticals Inc. | 11 | $114 |
| Esperion Therapeutics, Inc. | 8 | $108 |
| Astellas Pharma US Inc | 6 | $106 |
| Bayer | 6 | $95 |
| Novartis | 6 | $91 |
| Abbott | 6 | $90 |
| Exact Sciences | 4 | $71 |
| Amgen | 5 | $66 |
| Boehringer Ingelheim | 3 | $46 |
| Ardelyx, Inc. | 2 | $40 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $36 |
| Amarin Pharma, Inc. | 2 | $35 |
| Lundbeck LLC | 2 | $30 |
| Avanir Pharmaceuticals, Inc. | 2 | $28 |
| Vanda Pharmaceuticals Inc. | 1 | $21 |
| Urovant Sciences Inc | 1 | $20 |
| UCB, Inc. | 1 | $17 |
| Neurocrine Biosciences, Inc. | 1 | $15 |
| Kowa Pharmaceuticals America, Inc. | 1 | $15 |
| Ironwood Pharmaceuticals, Inc | 1 | $14 |
| Idorsia Pharmaceuticals US Inc | 1 | $13 |
| Genentech USA, Inc. | 1 | $3 |
How this compares
$7,115 in reported general payments places this provider in the 95th percentile of 3,610 family providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 117 | $150,395 |
| JardianceEmpagliflozin | 133 | $120,998 |
| OzempicSemaglutide | 132 | $120,872 |
| FarxigaDapagliflozin Propanediol | 77 | $52,228 |
| EliquisApixaban | 75 | $51,526 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 44 | $37,601 |
| LinzessLinaclotide | 54 | $34,500 |
| TrulicityDulaglutide | 27 | $25,463 |
| XareltoRivaroxaban | 31 | $24,547 |
| JanuviaSitagliptin Phosphate | 35 | $21,576 |
| RexultiBrexpiprazole | 13 | $19,751 |
| MyrbetriqMirabegron | 24 | $16,079 |
| EntrestoSacubitril/Valsartan | 18 | $15,975 |
| TrintellixVortioxetine Hydrobromide | 12 | $12,355 |
| Spiriva RespimatTiotropium Bromide | 14 | $6,965 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Olanzapine | $295 | $177,542189 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat | $46 | $127,963147 claims |
| Novo NordiskOzempic | $820 | $120,872132 claims |
| AstraZenecaFarxiga | $583 | $52,22877 claims |
| PfizerEliquis | $184 | $51,52675 claims |
| GSKTrelegy Ellipta | $448 | $37,60144 claims |
| AbbVieLinzess | $2,178 | $34,50054 claims |
| MerckJanuvia | $240 | $21,57635 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $237 | $19,75113 claims |
| Astellas Pharma US IncMyrbetriq | $106 | $16,07924 claims |
| NovartisEntresto | $91 | $15,97518 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $218 | $12,35512 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,610 family providers in Louisiana.
Other family in Woodworth
- Rebecca EzellSlidell$268K
- Erin PierceNew Orleans$261K
- Tavell KindallNew Orleans$194K
- Ashlea HillRuston$169K
- Brittany MillerVille Platte$158K
- Ryanne ClarkeGretna$123K
- Elidia DewittBaton Rouge$108K
- Rebekah GarrardLafayette$105K
- Tiffany RoeShreveport$97K
- Ghenet GhebretatiosBaton Rouge$91K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.